ACADIA Pharmaceuticals Inc. (ACAD)

25.96
NASDAQ : Health Technology
Prev Close 25.34
Day Low/High 25.45 / 26.10
52 Wk Low/High 12.77 / 28.67
Avg Volume 1.31M
Exchange NASDAQ
Shares Outstanding 144.17M
Market Cap 3.65B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
8 Stocks Poised to Change Direction

8 Stocks Poised to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns.

FDA Issues Statement Reaffirming The Positive Benefit-Risk Profile Of NUPLAZID® (pimavanserin) For Patients With Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

FDA Issues Statement Reaffirming The Positive Benefit-Risk Profile Of NUPLAZID® (pimavanserin) For Patients With Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that the FDA has completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of NUPLAZID (pimavanserin) for patients with Parkinson's disease...

Interesting ACAD Put And Call Options For January 2021

Interesting ACAD Put And Call Options For January 2021

Investors in Acadia Pharmaceuticals Inc saw new options become available this week, for the January 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc.

Investors: The Law Offices Of Howard G. Smith Reminds Investors Of Lead Plaintiff Deadline In The Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD)

Investors: The Law Offices Of Howard G. Smith Reminds Investors Of Lead Plaintiff Deadline In The Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD)

Law Offices of Howard G. Smith reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc.

Analyses Of Pimavanserin Studies Evaluating Treatment In Alzheimer's Disease Psychosis And Parkinson's Disease Psychosis Published In The Journal Of Prevention Of Alzheimer's Disease Suggest Potential For Treating Dementia-Related Psychosis

Analyses Of Pimavanserin Studies Evaluating Treatment In Alzheimer's Disease Psychosis And Parkinson's Disease Psychosis Published In The Journal Of Prevention Of Alzheimer's Disease Suggest Potential For Treating Dementia-Related Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced today publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and efficacy of pimavanserin for the treatment of psychosis in Alzheimer's...

ACADIA Pharmaceuticals To Present At The Morgan Stanley 16th Annual Global Healthcare Conference On September 13, 2018

ACADIA Pharmaceuticals To Present At The Morgan Stanley 16th Annual Global Healthcare Conference On September 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc.

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc.

First Week Of October 19th Options Trading For Acadia Pharmaceuticals (ACAD)

First Week Of October 19th Options Trading For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc.

ACADIA Pharmaceuticals And Neuren Pharmaceuticals Announce Exclusive License Agreement For The North American Development And Commercialization Of Trofinetide In Rett Syndrome

ACADIA Pharmaceuticals And Neuren Pharmaceuticals Announce Exclusive License Agreement For The North American Development And Commercialization Of Trofinetide In Rett Syndrome

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome...

ACAD ALERT NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline - ACAD

ACAD ALERT NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline - ACAD

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals To Announce Second Quarter 2018 Financial Results On August 8, 2018

ACADIA Pharmaceuticals To Announce Second Quarter 2018 Financial Results On August 8, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.

Federman & Sherwood announces that on July 19, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of California against Acadia Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc.

Austin D. Kim, Executive Vice President, General Counsel And Secretary (Photo: Business Wire)

Austin D. Kim, Executive Vice President, General Counsel And Secretary (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ACADIA Pharmaceuticals Inc. - ACAD

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ACADIA Pharmaceuticals Inc. - ACAD

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ACADIA Pharmaceuticals Inc.

August 24th Options Now Available For Acadia Pharmaceuticals (ACAD)

August 24th Options Now Available For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading today, for the August 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new August 24th contracts and identified one put and one call contract of particular interest.

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with...

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

First Week Of July 20th Options Trading For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D (Sell)